Corrigendum

# The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study

**Guttorm Raknes[a,b] , Pia Simonsen[c], Lars Småbrekke[d]**

[a]Regional Medicines Information and Pharmacovigilance Centre [RELIS], University Hospital of North Norway, Tromsø, Norway [b]Raknes Research, Ulset, Norway [c]Vitus Apotek, Vikersund, Norway [d]Department of Pharmacy, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromsø, Norway

There were some errors in Table 3, Supplementary data 3 and Supplementary data 5 in the original article. These have now been corrected in the online version.

The method used (*Altman) is not available in standard statistics packages, and had to be performed in Excel. When calculating p-values from Z-scores, the Excel function =NORM.S.DIST was mistakenly used. This gives approximately correct *p*-values for high Z-scores (statistical significant results), but the maximum max *p*-value output for this function is 0,4.

There are no results where the statistical significance status is changed. The differences in *p*-values is mainly affecting the most non-significant values making *p*-values larger. The results, conclusions and scientific understanding of the study remain unchanged.

**Table 3:** Number of prevalent users of disease modifying medication in Norwegian patients with inflammatory bowel disease two years before and after first dispense of low dose naltrexone (LDN). Three groups based on number of LDN dispenses: LDN x 1 (N = 189) collected LDN once, LDN x 2-3 (N = 137) two or three times and LDN x 4+ (N = 256) four or more times. Other systemic immunosuppressants include azathioprine, methotrexate, mercaptopurine, cyclosporine, and tacrolimus.

| | | Users before LDN | | Users after LDN | | % points change in number of users | | *p* |
|---|---|---|---|---|---|---|---|---|
| | | N | % | N | % | | 95% CI | |
| All outcome drugs | *LDN x1* | 139 | 73.5 | 141 | 74.6 | 1.1 | (-6.8 to 9.0) | 0.793 |
| | *LDN x 2-3* | 109 | 79.6 | 98 | 71.5 | -8.0 | (-15.6 to -0.4) | 0.043 |
| | *LDN x 4+* | 216 | 84.4 | 191 | 74.6 | -9.8 | (-15.3 to -4.2) | 0.001 |
| Systemic immunosuppressants | *LDN x1* | 93 | 49.2 | 95 | 50.3 | 1.1 | (-6.6 to 8.7) | 0.786 |
| | *LDN x 2-3* | 73 | 53.3 | 69 | 50.4 | -2.9 | (-11.0 to 5.2) | 0.481 |
| | *LDN x 4+* | 137 | 53.5 | 121 | 47.3 | -6.3 | (-12.4 to -0.1) | 0.050 |
| Systemic corticosteroids | *LDN x1* | 71 | 37.6 | 71 | 37.6 | 0.0 | (-8.3 to 8.3) | 1.000 |
| | *LDN x 2-3* | 60 | 43.8 | 54 | 39.4 | -4.4 | (-12.9 to 4.2) | 0.319 |
| | *LDN x 4+* | 107 | 41.8 | 92 | 35.9 | -5.9 | (-12.4 to 0.6) | 0.080 |
| TNF-α inhibitors | *LDN x1* | 32 | 16.9 | 30 | 15.9 | -1.1 | (-6.5 to 4.4) | 0.706 |
| | *LDN x 2-3* | 14 | 10.2 | 15 | 10.9 | 0.7 | (-4.8 to 6.3) | 0.797 |
| | *LDN x 4+* | 27 | 10.5 | 25 | 9.8 | -0.8 | (-4.3 to 2.0) | 0.468 |
| Other systemic immunosuppressants | *LDN x1* | 39 | 20.6 | 33 | 17.5 | -3.2 | (-8.4 to 2.1) | 0.241 |
| | *LDN x 2-3* | 23 | 16.8 | 28 | 20.4 | 3.6 | (-3.2 to 10.5) | 0.299 |
| | *LDN x 4+* | 45 | 17.6 | 32 | 12.5 | -5.1 | (-8.8 to -1.3) | 0.010 |
| Intestinal anti-inflammatory agents | *LDN x1* | 109 | 57.7 | 102 | 54.0 | -3.7 | (-11.8 to 4.4) | 0.371 |
| | *LDN x 2-3* | 82 | 59.9 | 72 | 52.6 | -7.3 | (-15.8 to 1.2) | 0.098 |
| | *LDN x 4+* | 168 | 65.4 | 140 | 54.5 | -10.9 | (-17.0 to -4.7) | 0.001 |
| Intestinal corticosteroids | *LDN x1* | 42 | 22.2 | 46 | 24.3 | 2.1 | (-4.4 to 8.7) | 0.528 |
| | *LDN x 2-3* | 40 | 29.2 | 36 | 26.3 | -2.9 | (-11.7 to 5.9) | 0.518 |
| | *LDN x 4+* | 53 | 20.7 | 36 | 14.1 | -6.6 | (-11.7 to -1.6) | 0.012 |
| Aminosalicylates | *LDN x1* | 89 | 47.1 | 78 | 41.3 | -5.8 | (-12.7 to 1.1) | 0.103 |
| | *LDN x 2-3* | 58 | 42.3 | 50 | 36.5 | -5.8 | (-11.8 to 0.2) | 0.061 |
| | *LDN x 4+* | 139 | 54.3 | 116 | 45.3 | -9.0 | (-14.3 to -3.6) | 0.001 |